Prostate Cancer News

XTANDI becomes the first and only androgen receptor signaling inhibitor approved for use with or without a GnRH analog therapy* in nonmetastatic castration-sensitive prostate cancer.

Dr. Alicia Morgans emphasizes the importance of educating prostate cancer patients and caregivers through trusted resources, like the Prostate Cancer Foundation and ZERO Prostate Cancer, and encourages open communication with medical teams, addressing topics such as cancer curability, treatment options, sexual health, mental health, and the need for support in the context of prostate cancer care.

A new bill in D.C. aims to reduce high prostate cancer fatality rates, especially among black men, by mandating annual insurance coverage for prostate cancer screenings, addressing disparities in access to testing and improving early diagnosis for better survival rates.

Prostate cancer screening methods are under review for better targeting high-risk groups and addressing stagnant death rates and late-stage diagnoses.

More men with prostate cancer could afford to delay their treatment, a decades-long study has found, suggesting that active monitoring by health-care professionals is an equally valid — and less harsh — option.

Several years ago, medical oncologist Samuel Denmeade, M.D., Co-Director of the Johns Hopkins Prostate Cancer Program, and colleagues came up with a remarkable concept for attacking prostate cancer: alternating androgen deprivation therapy (ADT) with high-dose testosterone.